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Abstract 44 
To assess the excess risk of HPV-associated cancer (HPVaC) in two at-risk groups – women with a previous 45 
diagnosis of high grade cervical intraepithelial neoplasia (CIN3) and both men and women treated for non-46 
cervical pre-invasive ano-genital disease. 47 
All CIN3 cases diagnosed in 1989-2015 in Scotland were extracted from the Scottish cancer registry (SMR06). All 48 
cases of pre-invasive penile, anal, vulval, and vaginal disease diagnosed in 1990-2015 were identified within the 49 
NHS pathology databases in the two largest NHS health boards in Scotland. Both were linked to SMR06 to extract 50 
subsequent incidence of HPVaC following the diagnosis of CIN3 or pre-invasive disease. Standardised incidence 51 
ratios were calculated for the risk of acquiring HPVaC for the two at-risk groups compared with the general 52 
Scottish population. 53 
Among 69714 females in Scotland diagnosed with CIN3 (890360.9 person-years), 179 developed non-cervical 54 
HPVaC. CIN3 cases were at 3.2-fold (95% CI: 2.7 to 3.7) increased risk of developing non-cervical HPVaC, 55 
compared to the general female population. Among 1235 patients diagnosed with non-cervical pre-invasive 56 
disease (9667.4 person-years), 47 developed HPVaC. Individuals with non-cervical pre-invasive disease had a 57 
substantially increased risk of developing HPVaC - 15.5-fold (95% CI: 11.1 to 21.1) increased risk for females and 58 
28-fold (11.3 to 57.7) increased risk for males. 59 
We report a significant additional risk of HPV-associated cancer in those have been diagnosed with pre-invasive 60 
HPV-associated lesions including but not confined to the cervix. Uncovering the natural history of pre-invasive 61 
disease has potential for determining screening, prevention and treatment.  62 
 63 
Summary box 64 
What is already known? 65 
A history of CIN3 confers a significant risk of HPV-associated cancer. 66 
What is this study adds? 67 
A history of non-cervical ano-genital pre-invasive disease is associated with significant additional risk of HPV 68 
associated cancer. 69 
Determining risk of pre-invasive disease has potential for determining screening, prevention and treatment 70 
strategies. HPV vaccination for this high-risk group may provide benefit.  71 
Introduction 72 
The incidence of human papillomavirus (HPV)-associated, non-cervical cancers is increasing globally and 73 
Scotland is no exception. The increase in incidence of oropharyngeal cancer (OPC) has been the best 74 
documented and evidence that the HPV positive status in OPC confers an improved clinical outcome has focused 75 
much research into finding an explanation for this observation. However, other non-cervical genital HPV 76 
associated cancers are also increasing and this is less documented in the literature as is, arguably, the role of 77 
HPV status in the clinical outcome of those affected.  In Scotland, the age-standardised incidence of cancers of 78 
the anus, penis, vagina and vulva rose by 1.6, 1.1, 0.1 and 0.9 per 100,000 respectively during 1970 – 2014 [1]. 79 
This trend is mirrored elsewhere in countries that have robust cancer registry data [2]. 80 
Reasons for the increase in cancers of the anus, penis and vulva are not fully understood although an increase 81 
in HPV infection supported by temporal changes in sexual practices and behaviors has been suggested. 82 
Individuals interviewed as part of the National Survey of Sexual Attitudes and Lifestyles (NATSAL) report younger 83 
age of first intercourse, increased number of lifetime heterosexual partners and an increase in the number of 84 
individuals reporting same-sex experience compared to earlier surveys [3]. In the USA, inferred trends in sexual 85 
behaviour over the past decades have paralleled the increasing incidence of HPV-related cancers [4]. This said, 86 
the differential influence of risk factors, including and beyond sexual behaviours makes the generation of a broad 87 
conclusion to explain this increase challenging. 88 
It is important to monitor incidence of these neoplasms to determine the associated morbidity and mortality 89 
that could be preventable by HPV vaccination in future generations. However, the current HPV vaccines will not 90 
wholly protect individuals already infected with HPV, nor prevent disease associated with all 13 oncogenic types. 91 
As a consequence, the challenge remains of how to optimally manage and treat what can be particularly morbid 92 
cancers from a clinical and psychological perspective. To this end, a clear understanding of their epidemiology 93 
will help inform the requirement and nature of interventions for their detection, management and treatment. 94 
The national organized cervical screening programme was introduced in Scotland in 1988 with the aim of 95 
reducing the incidence of invasive cancer of the cervix and has been a success. The European age standardized 96 
rate of invasive cervical cancer has reduced from 18/100,000 in 1988 to 10/100,000 in 2009, rising subsequently 97 
to 13/100,000 in 2015. The percentage of eligible women who were recorded as screened adequately was 73.4% 98 
[4]. However, in Scotland there is currently no coordinated/ organized surveillance for non-cervical genital 99 
cancers in any population group or guidance for surveillance of these sites in high risk groups except for 100 
enhanced cervical screening in HIV-positive women. This raises the concern that early diagnosis of curable non-101 
cervical genital cancers may be missed despite individuals being seen regularly by medical services.  102 
Furthermore, gaining an understanding of particular groups who may be at increased risk of non-cervical genital 103 
cancers could aid a focused and standardised approach to the monitoring. 104 
We have used national population data available in Scotland to systematically assess the excess risk of HPV-105 
associated disease compared to the general population in two populations perceived to be at additional risk of 106 
associated disease: (a) women with a history of CIN 3 and (b) individuals with a history of non-cervical pre-107 
invasive disease.   108 
Methods 109 
Data collation for women diagnosed with CIN3 and assessment of subsequent cancer risk 110 
A retrospective cohort study of national data was performed in order to estimate the risk of HPV associated 111 
cancers (HPVaC) in those diagnosed with CIN 3.  All individuals resident in Scotland are uniquely identified in 112 
National Health Service (NHS) datasets via their community health index (CHI) number.   All cases of CIN3 (ICD10: 113 
233.1) were extracted from the Scottish Cancer Registry (SMR06) [6].  As full introduction of national cervical 114 
cancer screening was introduced in 1988 [5], extraction of CIN3 from SMR06 was limited to Jan 1989 - Dec 2015 115 
(with the latter year representing the most recent year for which data was available at time of extraction). 116 
Variables collected were gender, date of birth, health board and date of diagnosis of CIN3. All individuals with 117 
CIN3 were then linked to SMR06 to extract incidence of HPVaC (tonsil, base of tongue, soft palate, oropharynx 118 
not otherwise specified, cervix, vulva, vagina, penis, anus) (ICD10: C09, C01, C05, C10, C53, C51, C52, C60, C21, 119 
respectively) in addition to rectal cancer (ICD10: C20) which was used as a baseline comparator with no known 120 
association with HPV.  Cancers with evidence of both vaginal and cervical malignancy were classified as cervical 121 
cancer. The analysis focussed on individuals over 18 years old given that over 95% of cancers listed above are 122 
diagnosed after this age [1].  Date of death/emigration was also captured in order to obtain the date of censoring 123 
due to loss of follow-up. 124 
 125 
Data collation for individuals diagnosed with pre-invasive penile, anal, vulval and vaginal disease and assessment 126 
of subsequent cancer risk 127 
All cases of pre-invasive penile, anal, vulval and vaginal disease and invasive malignancy diagnosed between 128 
1990 and 2015 were identified within the NHS pathology databases associated with the two largest health 129 
boards in Scotland – NHS Greater Glasgow and Clyde (GGC) and NHS Lothian that together cover 2 million people 130 
and thus around 40% of the Scottish population. Data, collected as part of routine clinical care, on gender, date 131 
of birth, health board, date of diagnosis and degree of dysplasia were extracted. Subsequent HPVaC, rectal 132 
cancer and date of death/emigration were linked from national data as explained previously. 133 
 134 
Statistical analysis 135 
For each of the two at-risk populations, person time at risk and the number of observed cancers were stratified 136 
by age group in 5 year bands (18-19, 20-24, 25-30,…, 84-89, 90+), gender and year of diagnosis. The expected 137 
numbers of cancers occurring among the at-risk population, assuming the same incidence as that observed for 138 
the general population in Scotland (for patients with CIN3 history) or in GGC and Lothian (for pre-invasive cohort) 139 
stratified by the same age groups, gender and year of cancer diagnosis, was calculated by multiplying the person 140 
time at risk in each group by the corresponding average cancer incidence. The Standardised Incidence Ratio (SIR) 141 
was defined as the ratio of the observed to expected number of cancers and the confidence interval (CI) was 142 
calculated assuming that the observed number followed a Poisson distribution. 143 
We excluded patients with a diagnosis of any HPVaC before a diagnosis of CIN3 or pre-invasive non-cervical 144 
disease. The person time at risk started counting at one year after CIN3 or pre-invasive non-cervical disease 145 
diagnosis and ended at earlier incidence of first HPVaC, death, emigration or the end of study (2015-12-31). 146 
Those with an HPVaC occurring within one year of CIN3 or pre-invasive non-cervical disease diagnosis were 147 
excluded in the baseline analysis to avoid mis-classification of concurrent disease as sequential disease events. 148 
A sensitivity analysis, considering an exclusion time of 0, 3, 6, 9 months, was conducted to examine the influence 149 
of this exclusion upon the results. 150 
All analysis was conducted using R version 3.2.1.  151 
Results 152 
Risk of HPVaC following CIN3 diagnosis 153 
Overall, 72153 women in Scotland had a diagnosis of CIN3 recoded in SMR06 between 1989-2015. Figure 1 154 
presents the denominators of the at-risk populations, related exclusions and start and end point(s) of the 155 
analysis. After excluding the patients with HPVaC before or during the year directly after the diagnosis of CIN3, 156 
the denominator reduced to 69714, contributing 890360.9 person years (Table 1). The CIN3 population had a 157 
median of age of diagnosis of 30 (IQR 26-36) and of these 490 women had a diagnosis of any HPVaC more than 158 
one year after diagnosis of CIN3 corresponding to an SIR of 2.3 (95% CI 2.1-2.5) compared to the general female 159 
population in Scotland (Table 1). 160 
The risk of developing a non-cervical HPVaC varied by the anatomical subtype - SIR ranged from 2.3 (95% CI 1.6-161 
3.2) for oropharyngeal cancer to 9.6 (95% CI 7-13) for vaginal cancer (Table 1).  The risk among women with CIN3 162 
for anal and vulvar cancer was increased by more than 2-fold compared to the general female population.  The 163 
SIR for non-HPV related rectal cancer did not differ substantially from unity (SIR = 1.1 95% CI 0.9-1.5) (Table 1).   164 
The SIR for developing any non-cervical HPVaC in the context of a cervical screening programme was higher than 165 
that for cervical cancers (SIR for non-cervical HPVaC = 3.2, 95% CI 2.7-3.7; SIR for cervical cancer = 2.0, 95% CI 166 
1.8-2.2) (Table 2).  The SIR for non-cervical HPVaC increased with age at diagnosis CIN3 (SIR = 3.1 95% CI 2.2-4.1 167 
for age <=30; SIR = 7.4 95% CI 0.9-26.8 for age >70).  There was no time trend identified for the risk of non-168 
cervical HPVaC by year of diagnosis of CIN3. Interestingly, there was no reduction in risk of developing a non-169 
cervical HPVaC with increasing time from CIN3 diagnosis; the risk between 1-2 years from CIN3 diagnosis was 170 
similar to that more than 20 years after CIN3 diagnosis. 171 
The risk of cervical cancer was significantly increased in all birth cohorts, except for the women born after 1965, 172 
for whom the risk did not differ from the general population. The greatest risk of cervical cancer was observed 173 
in the oldest cohort (women born before 1935: SIR = 10.1 95% CI 5.8-16.4; born 1936-1945: SIR = 7.4 95% CI 5-174 
10.4). The risk of cervical cancer was increased in all ages when diagnosed after 30 years, with an increasing SIR 175 
for those diagnosed CIN3 at older age (SIR = 2.5 95% CI 2.1-3 for age 31-40; SIR = 14.3 95% CI 1.7-51.6 for age 176 
>70).  There was no time trend observed in SIR by year of diagnosis of CIN3 and there was no decreasing trend 177 
in SIR for time since the CIN3 diagnosis – even after 20 years since diagnosis of CIN3 there remained an increased 178 
risk of cervical cancer (SIR = 2.6, 95% CI 1.6-4.1). 179 
 180 
Risk of HPVaC following after non-cervical pre-invasive disease 181 
Overall, 2309 patients had a diagnosis of pre-invasive (all degrees of dysplasia) and invasive penile, anal, vulvar 182 
and vaginal disease in GGC and Lothian. After excluding the patients with HPVaC before or during the year 183 
directly after the diagnosis of pre-invasive disease, the denominator for analysis reduced to 1235 (Figure 1). For 184 
each anatomical site of dysplasia, the majority were classified as severe dysplasia or dysplasia NOS (n=782, 185 
63.3%) with a small proportion classified as having mild or moderate dysplasia (Table A2). For the cohort of each 186 
dysplasia site, the median age ranged from 41 (Interquartile range (IQR) 35-47) year for female perineum and 187 
57 (IQR 39-64.5) years for penis (Table A2). 188 
Overall 1035 women had pre-invasive disease in the ano-genital region (vagina, vulva, perineum and anus), 189 
contributing 8464.5 person years of follow-up (Table 3). Among them, 40 developed HPVaC one year or more 190 
after the diagnosis of pre-invasive ano-genital disease. Compared to the general female population resident in 191 
GGC and Lothian, the incidence of HPVaC for women with a history of pre-invasive disease was 15.5 times higher 192 
(95% CI 11.1-21.1). The SIR was highest for the patients with anal dysplasia (SIR = 38.9 95% CI 15.6-80.1) but 193 
lower for those with vaginal dysplasia (SIR = 9.4 95% CI 4.3-17.8). 194 
198 male patients had pre-invasive anogenital disease (penis, perineum and anus), contributing 1202.9 person 195 
years (Table 3). Among them, 7 developed HPVaC one year or more after the diagnosis of pre-invasive disease. 196 
Compared to the male population resident in GGC and Lothian, the SIR for men with a history of pre-invasive 197 
ano-genital disease to develop HPVaC was 28 (95% CI 11.3-57.7). The risk of cancer was highest for the patients 198 
with anal dysplasia (SIR = 36.4 95% CI 9.9-93.1) and lowest for those with penile dysplasia (SIR = 21.4 95% CI 4.4-199 
62.6). 200 
 201 
Sensitivity analysis 202 
Sensitivity analysis was conducted for the CIN3 cohort to investigate the effect of changing the cancer exclusion 203 
period from the baseline choice of 1 year to 0, 3, 6 or 9 months. If no exclusion was applied, 631 cervical cancer 204 
cases were observed among CIN3 patients (SIR = 3.8), likely representing concurrent diagnosis. When a 3 months 205 
exclusion period was used, 374 cervical cancer cases were observed (SIR = 2.3) – similar to baseline analysis of 206 
1 year (SIR = 2).  The SIR did not materially change for developing non-cervical genital cancers when different 207 
exclusion periods were applied (Table A1). 208 
For the non-cervical pre-invasive cohort, 741 patients with prior HPVaC were excluded for the following reasons: 209 
1) the site of the pre-invasive disease matched the site of the prior HPVaC (Table A3); 2) The time difference 210 
between the diagnosis of pre-invasive and prior HPVaC was short (median 60 days IQR 20-238). Sensitivity 211 
analysis was performed again changing the exclusion period from 1 year to 0, 3, 6 and 9 months. SIRs for 212 
exclusion period of 3, 6 and 9 months were close to the baseline results (Table A4). However if no exclusion 213 
period was applied, a higher number of subsequent HPVaC cases was observed and the SIR inflated substantially 214 
compared to the baseline analysis.  215 
Discussion 216 
In the present evaluation which spanned 36 years and incorporated national data, we describe two groups at 217 
substantially increased risk of HPV associated cancer: those who have been diagnosed with high grade cervical 218 
lesions and those who have been treated for non-cervical pre-invasive disease to any degree.  Notably, women 219 
who have had a CIN3 diagnosis (identified via screening) were at 3.2 fold increased risk of developing a non-220 
cervical HPVaC (including a 9.6-fold risk of developing vaginal cancer) compared to the general female 221 
population in Scotland. In addition, individuals with non-cervical pre-invasive disease had a substantially 222 
increased risk of developing HPVaC, reflected as a 15.5 fold and 28 fold increased risk for females and males 223 
respectively compared to the general population. The additional risk was highest in patients with pre-invasive 224 
disease of the anus for both genders. 225 
In women diagnosed with CIN3, the greatest risk of both non-cervical and cervical HPVaC was associated with 226 
older age at diagnosis but the magnitude of that risk was unaffected by time since diagnoses. 227 
The observation that a history of CIN3 confers a significant risk of HPV associated cancer is consistent with other 228 
studies [7-14] such as the one performed by Kalliala and colleagues [10] who reported SIRs for vulvar, vaginal 229 
and anal canal cancer as 4.1 (95% CI: 1.5-8.9), 12 (2.9-28) and 5.7 (1.2-17) respectively. Strander et al [11] also 230 
reported SIRs for cervical and vaginal cancer as 2.3 (2.2-2.5) and 6.8 (5.6-8.2). Ebisch et al [14] reported incidence 231 
rate ratios for anal, vulvar, vaginal and oropharyngeal cancer as 3.9 (2.3-6.4), 5 (3.3-7.6), 86.1 (12-618.1) and 5.5 232 
(1.2-24.8). In our study, SIRs for cervical, vulvar, vaginal and anal cancer were 2 (1.8-2.2), 2.8 (2.2-3.6), 9.6 (7-233 
13), and 2.6 (1.9-3.6), which are in line with the Nordic studies [10,11], notwithstanding the fact that the authors 234 
did not exclude the patients with a previous diagnosis of HPVaC as we have in the present analysis. Strander et 235 
al and Ebisch et al document a duration of risk of at least 20 years, similar to the present findings [11,12,14].  236 
The risk of HPV associated cancer in those with non-cervical pre-invasive disease is not well documented in the 237 
literature in contrast to the risk after CIN3. There is a particular paucity of studies which have taken into account 238 
large national data sets; rather the existing literature has focussed more on small cohort studies of HPV 239 
associated disease progression at a particular site with no comparator/control group [15,16]. Joura et al [17] 240 
reported that compared with those who underwent cervical surgery, those who were diagnosed with vulvar 241 
disease were at nearly 3 fold increased risk of developing any subsequent HPV related disease. To our knowledge 242 
the present analysis represents the first population based study of risk with comparison/contextualisation to 243 
the general population. 244 
Ideally, screening or surveillance guidelines and management strategies should take into account the additional 245 
risks conferred on those with pre-invasive disease. This is easier to apply for cervical disease given the existence 246 
of an organised screening programme.  Most countries that offer cervical screening now offer molecular HPV 247 
testing as part of post treatment follow up of CIN [18]. Further developments in the cervical screening in the UK 248 
(and beyond) which include the implementation of primary screening using molecular HPV testing are likely to 249 
identify those at risk of subsequent cervical disease earlier as demonstrated in trials of HPV vs Cytology 250 
screening, [19,20]. The sensitivity and earlier “warning” signal of an HPV test may thus deliver benefits to those 251 
with (any) HPV associated pre-invasive disease although this was not specifically investigated in the 252 
aforementioned trials. Furthermore, treatment for women with CIN3 by the gynaecologists should also include 253 
inspection of vaginal, vulva and perineum. 254 
The most effective strategy to manage non-cervical HPV associated disease is more challenging.  There is no 255 
population based screening programme or surveillance for AIN in Scotland, and so the risks reported in this study 256 
are likely to underestimate its occurrence. Screening for anal disease has been considered using a variety of 257 
approaches (cytology, high resolution anoscopy, HPV testing, biomarkers and various combinations thereof). 258 
However, currently, there is no evidenced, effective model for an anal screening and treatment pathway that 259 
would reduce risk of anal cancer. Given that treatment of anal lesions is associated with significant morbidity, 260 
further research is required. Longitudinal studies such as the Australian Study of the Prevention of anal cancer 261 
“SPANC” which monitors viral,  cytopathological and anoscopy outcomes over time in an MSM population will 262 
be helpful in this regard  [21,22]. 263 
Notwithstanding the limitations of the data on anal screening, arguably considerably more attention and 264 
research has been channelled into this area compared to screening for other non-cervical HPV associated 265 
cancers. This is likely attributable to the comparative rarity of penile, vulvar, & vaginal cancer, and the fact that 266 
OPC does not have a monitorable precursor phase, with patients presenting with symptomatic disease.  Kreimer 267 
et al [23,24] showed that HPV-16 E6 serology can identify those at greater risk of subsequent anal and 268 
oropharyngeal cancer but not other HPV associated cancers; HPV16 E6 seropositivity was present in 29.2% of 269 
individuals who later developed anal cancer compared with 0.6% of controls [24] and in the prediagnostic 270 
samples of 34.8% of patients with oropharyngeal cancer and 0.6% of controls [23].   271 
Another important point for consideration is why those with preinvasive lesions are at additional risk of 272 
subsequent cancer.  Part of this explanation could of course be to do with the continuation of risk-associated 273 
behaviours after the initial diagnosis (including the key factors of smoking and social deprivation) which we did 274 
not assess in this study. Similarly, while Strander et al [12] adjusted for follow-up duration, treatment period, 275 
and age at treatment the authors did not adjust for behavioural/environmental influences. This said, the CIN3 276 
population described in the present analysis represented women who were engaged in cervical screening. The 277 
study population was thus biased towards those from less deprived backgrounds with a lower risk of HPV 278 
infection and disease [25].  However, future studies which endeavour to capture behavioural data or surrogates 279 
will be important to (a) determine the key behavioural factors that confer risk of subsequent disease which could 280 
inform focussed management (b) quantify the extent of risk which remains after adjustment for such factors. 281 
With respect to the latter, it is entirely plausible that the efficacy and capacity of innate immune responses play 282 
a continued role in the susceptibility to HPV associated disease [26]. Only 5% of those infected with HR-HPV 283 
develop high grade cervical lesions the majority of which will resolve naturally, but immunocompromised 284 
patients have a higher risk of developing high grade disease [27-30]. However, the lack of understanding of the 285 
mechanisms determining persistence makes development of a therapeutic vaccine challenging. A further factor 286 
is the widespread colonisation of ano-genital, perineal and oral squamous mucosa by HPV. Treatment at one 287 
site in the absence of other measures to promote HPV clearance will not affect HPV burden at other infected 288 
sites, and so will not mitigate the risk of subsequent disease  289 
Although current HPV vaccines are delivered as prophylactic regimens i.e. before HPV infection, there may be 290 
merit in vaccinating high-risk groups with preinvasive lesions. It is possible to stimulate HPV-specific antibodies 291 
in older women who have previously been diagnosed with abnormal pap smears through quadrivalent 292 
vaccination [31]. Furthermore, adjuvant administration of quadrivalent HPV vaccine has been shown to be 293 
associated with a significant reduction in recurrent high-grade anal intraepithelial neoplasia (HGAIN) in MSM 294 
[32]. Joura et al demonstrated a significant reduction in HPV related vulvo-vaginal disease in women who had 295 
been both vaccinated and also treated following vaccination for cervical disease [17]. Opportunistic HPV 296 
vaccination for our high-risk populations may prove to be beneficial in preventing subsequent development of 297 
HPV-related cancers, while gender-neutral HPV immunisation is associated with profound decreases in most of 298 
the clinically relevant oncogenic HPV types and will significantly reduce risk of HPVaC in men and women with 299 
preinvasive non-cervical ano-genital disease [33]. 300 
In summary in this analysis we demonstrate the significant additional risk of HPV associated cancer in individuals 301 
who have been diagnosed with preinvasive lesions including but not confined to the cervix. Further investigation 302 
into mechanistic and behavioural drivers that explain this phenomenon will inform screening and therapeutic 303 
strategies.  Given the increasing incidence of HPV associated cancers in genital and non-genital sites within 304 
unvaccinated populations, this should be a priority for research. 305 
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